


The Invesco Perpetual Monthly Income Plus Fund aims to achieve a high level of income whilst seeking to maximise total return through investing in high yielding corporate and Government bonds, together with UK equities.
| Name | % Net Assets | 
|---|---|
| AstraZeneca | 6.2% | 
| UK Treasury | 3.1% | 
| Linde 8.125% £ Bonds 14/7/2016 | 2.6% | 
| SLM 5.375% £ Bonds 15/12/2010 | 2.6% | 
| UPC | 2.4% | 
| Rhodia € FRN 15/10/2013 | 1.1% | 
| Rexam 6.75% € Bonds 29/6/2017 | 1.1% | 
| BG | 1.0% | 
| Intergen 9.5% £ Bonds 30/6/2017 | 1.0% | 
| Reynolds American | 1.0% | 
| Key | % Net Assets | 
|---|---|
| 6.2% | |
| 3.1% | |
| 2.6% | |
| 2.6% | |
| 85.5% | 
| Date | 20-Aug-2025 | 
|---|---|
| NAV | 93.84p | 
| Currency | GBP | 
| Change | 0.19p | 
| % | 0.20% | 
| YTD change | 0.20p | 
| YTD % | 0.21% | 
| Fund Inception | 06/02/1999 | 
|---|---|
| Fund Manager | Paul Causer / Paul Read / Neil Woodford | 
| TER | 1.44 (31-Dec-2013) | 
| Minimum Investment | |
|---|---|
| Initial | £500 | 
| Additional | £100 | 
| Savings | £20 | 
| Charges | |
|---|---|
| Initial | 5.00% | 
| Annual Mang't | 1.42% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| Standard deviation | 0.00 | 
| Sharpe ratio | 0.53 | 
You are here: research